Skip to content

The therapeutic effects of camel milk and chicory inulin in autistic children

Evaluation of the effects of camel milk and chicory inulin on clinical problems and oxidative stress biomarkers in children with autism spectrum disorders

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20181227042147N1
Enrollment
99
Registered
2019-05-25
Start date
2019-05-27
Completion date
Unknown
Last updated
2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism spectrum disorder. Autistic disorder

Interventions

Intervention 1: Intervention group 1: will receive for 7 weeks both their routine treatment and 10 ml/kg body weight camel milk daily in 2 divided doses. To comply with sanitary ordinances, camel milk

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 15 Years

Inclusion criteria

Inclusion criteria: children with DSM 5 diagnosis of autism Ages between 3 and 15 years old

Exclusion criteria

Exclusion criteria: History of allergy to camel milk or chicory Inulin Chronic Infectious Diseases or AIDS Organic diseases Other Psychiatric and neurological disorders (for example: epilepsy, seizure, syndromes, ...) consuming camel milk consuming pre/probiotics’ products

Design outcomes

Primary

MeasureTime frame
Autism disorder Severity. Timepoint: At baseline and after 7 weeks of intervention. Method of measurement: Gilliam Autism Rating Scale-GARS- Questionnaire.;Evaluating the efficacy of treatment. Timepoint: At baseline and after 7 weeks of intervention. Method of measurement: Autism Treatment Evaluation Checklist (ATEC).

Secondary

MeasureTime frame
Superoxide Dismutase (SOD) activity. Timepoint: At baseline and end of intervention (after 7 weeks). Method of measurement: Spectrophotometry.;Total thiols concentration. Timepoint: At baseline and end of intervention (after 7 weeks). Method of measurement: Spectrophotometry.;Catalase activity. Timepoint: At baseline and end of intervention (after 7 weeks). Method of measurement: Spectrophotometry.;Malondialdehyde (MDA). Timepoint: At baseline and end of intervention (after 7 weeks). Method of measurement: Spectrophotometry.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Jamal Mirmoosavi

Mashhad University of Medical Sciences

mirmoosavij@medsab.ac.ir+98 51 3884 8930

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026